(Q44256483)

English

Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Helicobacter pylori

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

K Murakami

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

R Sato

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

T Okimoto

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

M Nasu

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

T Fujioka

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

M Kodama

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

J Kagawa

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

119-123

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Guidelines in the management of Helicobacter pylori infection in Japan

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Antibiotic resistance problems with Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Mechanism of metronidazole resistance in Helicobacter pylori: comparison of the rdxA gene sequences in 30 strains

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Cancer after exposure to metronidazole

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01401.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2003.01401.X

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44256483&oldid=2108943200"